AmSurg receives ‘strong buy’ rating for the short term: 4 facts

Zacks analysts gave AmSurg a “strong buy” rating for the short term, according to Money Flow Index.

Advertisement

Here are four facts:

1. On Monday, AmSurg shares traded at $83.38, down nearly 0.2 percent.

2. The 52-week high is $84.42 and 52-week low is $48.49.

3. The company has a market cap of nearly $4.04 billion.

4. AmSurg’s mean short term price target is $87.33 per share.

More articles on surgery centers:
Tenet Healthcare receives $40 price target: 5 takeaways
Alliance HealthCare Services, PRC Associates joint venture for interventional pain management: 5 things to know
16 hospitals & health systems opening ASCs — Nov. 10, 2015

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.